Arterial Occlusive Disease | Nanoparticle Imaging of Vascular Inflammation and Remodeling in Atherosclerotic Disease | springermedicine.com

Springer Medicine

Top

Current Cardiovascular Imaging Reports

Published in:

01-07-2019 | Arterial Occlusive Disease | Molecular Imaging (J Wu and P Nguyen, Section Editors)

Nanoparticle Imaging of Vascular Inflammation and Remodeling in Atherosclerotic Disease

Author: Darren G. Woodside

Published in: Current Cardiovascular Imaging Reports | Issue 7/2019

Login to get access

Abstract

Purpose of Review

The purpose of this review is to highlight some of the recent developments (within the last 5 years) in imaging atherosclerotic plaques using nanoparticles, with a focus on technologies that have been applied to in vivo models of disease.

Recent Findings

Structural and cellular components of atherosclerotic plaques are being imaged with greater definition and improved sensitivity. This is a result of both molecular targeting of nanoparticles to disease-relevant biomarkers through the use of nanoparticles of different shapes and sizes and tailoring pharmacokinetic parameters that allow for enhanced pharmacodynamic effects.

Summary

Currently, there are no atherosclerotic plaque imaging techniques clinically validated to predict future clinical events. Considering the rapid pace of new nanomaterial discovery and development, along with the development of multimodality imaging systems, this goal seems within reach. These advancements are “nano” in name only.

1.

World Health Organization. The top 10 causes of death. http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Acessed 15 Jan 2019.

2.

Vigne J, Thackeray J, Essers J, Makowski M, Varasteh Z, Curaj A, et al. Current and emerging preclinical approaches for imaging-based characterization of atherosclerosis. Mol Imaging Biol. 2018;20(6):869–87. https://doi.org/10.1007/s11307-018-1264-1.CrossRefPubMed

3.

Smith BR, Gambhir SS. Nanomaterials for in vivo imaging. Chem Rev. 2017;117(3):901–86. https://doi.org/10.1021/acs.chemrev.6b00073.CrossRefPubMed

4.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. https://doi.org/10.1056/NEJMoa1707914.CrossRefPubMed

5.

Koenig W. Inflammation revisited: atherosclerosis in the post-CANTOS era. Eur Cardiol. 2017;12(2):89–91. https://doi.org/10.15420/ecr.2017:18:1.CrossRefPubMedPubMedCentral

6.

Woodside DG, Tanifum EA, Ghaghada KB, Biediger RJ, Caivano AR, Starosolski ZA, et al. Magnetic resonance imaging of atherosclerotic plaque at clinically relevant field strengths (1T) by targeting the integrin alpha4beta1. Sci Rep. 2018;8(1):3733. https://doi.org/10.1038/s41598-018-21893-x.CrossRefPubMedPubMedCentral

7.

Bruckman MA, Jiang K, Simpson EJ, Randolph LN, Luyt LG, Yu X, et al. Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus. Nano Lett. 2014;14(3):1551–8. https://doi.org/10.1021/nl404816m.CrossRefPubMedPubMedCentral

8.

Chen W, Cormode DP, Vengrenyuk Y, Herranz B, Feig JE, Klink A, et al. Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression. JACC Cardiovasc Imaging. 2013;6(3):373–84. https://doi.org/10.1016/j.jcmg.2012.06.016.CrossRefPubMedPubMedCentral

9.

Yu M, Ortega CA, Si K, Molinaro R, Schoen FJ, Leitao RFC, et al. Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery. Theranostics. 2018;8(21):6008–24. https://doi.org/10.7150/thno.24365.CrossRefPubMedPubMedCentral

10.

Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, et al. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A. 2009;106(24):9815–9. https://doi.org/10.1073/pnas.0903369106.CrossRefPubMedPubMedCentral

11.

Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–16. https://doi.org/10.1038/nri3793.CrossRefPubMedPubMedCentral

12.

Nakayama M. Macrophage recognition of crystals and nanoparticles. Front Immunol. 2018;9:103. https://doi.org/10.3389/fimmu.2018.00103.CrossRefPubMedPubMedCentral

13.

Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278(5):483–93. https://doi.org/10.1111/joim.12406.CrossRefPubMedPubMedCentral

14.

Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251(4995):788–91.CrossRef

15.

Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107(10):1255–62. https://doi.org/10.1172/JCI11871.CrossRefPubMedPubMedCentral

16.

Patel SS, Thiagarajan R, Willerson JT, Yeh ET. Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation. 1998;97(1):75–81.CrossRef

17.

Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165–97. https://doi.org/10.1146/annurev.immunol.021908.132620.CrossRefPubMedPubMedCentral

18.

Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes. Circ Res. 2019;124(1):150–60. https://doi.org/10.1161/CIRCRESAHA.118.311098.CrossRefPubMed

19.

Reimann C, Brangsch J, Colletini F, Walter T, Hamm B, Botnar RM, et al. Molecular imaging of the extracellular matrix in the context of atherosclerosis. Adv Drug Deliv Rev. 2017;113:49–60. https://doi.org/10.1016/j.addr.2016.09.005.CrossRefPubMed

20.

Sinha A, Shaporev A, Nosoudi N, Lei Y, Vertegel A, Lessner S, et al. Nanoparticle targeting to diseased vasculature for imaging and therapy. Nanomedicine. 2014;10(5):1003–12. https://doi.org/10.1016/j.nano.2014.02.002.CrossRefPubMedPubMedCentral

21.

Perez-Medina C, Binderup T, Lobatto ME, Tang J, Calcagno C, Giesen L, et al. In vivo PET imaging of HDL in multiple atherosclerosis models. JACC Cardiovasc Imaging. 2016;9(8):950–61. https://doi.org/10.1016/j.jcmg.2016.01.020.CrossRefPubMedPubMedCentral

22.

Caravan P, Das B, Dumas S, Epstein FH, Helm PA, Jacques V, et al. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed Eng. 2007;46(43):8171–3. https://doi.org/10.1002/anie.200700700.CrossRef

23.

Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer. 2006;118(6):1331–9. https://doi.org/10.1002/ijc.21677.CrossRefPubMed

24.

Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res. 2004;95(12):1225–33. https://doi.org/10.1161/01.RES.0000150373.15149.ff.CrossRefPubMed

25.

Dietrich T, Berndorff D, Heinrich T, Hucko T, Stepina E, Hauff P, et al. Targeted ED-B fibronectin SPECT in vivo imaging in experimental atherosclerosis. Q J Nucl Med Mol Imaging. 2015;59(2):228–37.PubMed

26.

Kim H, Lee Y, Kang S, Choi M, Lee S, Kim S, et al. Self-assembled nanoparticles comprising aptide-SN38 conjugates for use in targeted cancer therapy. Nanotechnology. 2016;27(48):48LT01. https://doi.org/10.1088/0957-4484/27/48/48LT01.CrossRefPubMed

27.

Starmans LW, van Duijnhoven SM, Rossin R, Aime S, Daemen MJ, Nicolay K, et al. SPECT imaging of fibrin using fibrin-binding peptides. Contrast Media Mol Imaging. 2013;8(3):229–37. https://doi.org/10.1002/cmmi.1521.CrossRefPubMed

28.

Starmans LW, van Duijnhoven SM, Rossin R, Berben M, Aime S, Daemen MJ, et al. Evaluation of 111In-labeled EPep and FibPep as tracers for fibrin SPECT imaging. Mol Pharm. 2013;10(11):4309–21. https://doi.org/10.1021/mp400406x.CrossRefPubMed

29.

Starmans LW, Moonen RP, Aussems-Custers E, Daemen MJ, Strijkers GJ, Nicolay K, et al. Evaluation of iron oxide nanoparticle micelles for magnetic particle imaging (MPI) of thrombosis. PLoS One. 2015;10(3):e0119257. https://doi.org/10.1371/journal.pone.0119257.CrossRefPubMedPubMedCentral

30.

Yoo SP, Pineda F, Barrett JC, Poon C, Tirrell M, Chung EJ. Gadolinium-functionalized peptide amphiphile micelles for multimodal imaging of atherosclerotic lesions. ACS Omega. 2016;1(5):996–1003. https://doi.org/10.1021/acsomega.6b00210.CrossRefPubMedPubMedCentral

31.

Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A. 2007;104(3):932–6. https://doi.org/10.1073/pnas.0610298104.CrossRefPubMedPubMedCentral

32.

Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114(14):1504–11. https://doi.org/10.1161/CIRCULATIONAHA.106.646380.CrossRefPubMed

33.

Nahrendorf M, Keliher E, Panizzi P, Zhang H, Hembrador S, Figueiredo JL, et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging. 2009;2(10):1213–22. https://doi.org/10.1016/j.jcmg.2009.04.016.CrossRefPubMedPubMedCentral

34.

McAteer MA, Schneider JE, Ali ZA, Warrick N, Bursill CA, von zur Muhlen C, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol. 2008;28(1):77–83. https://doi.org/10.1161/ATVBAHA.107.145466.CrossRefPubMed

35.

Stein-Merlob AF, Hara T, McCarthy JR, Mauskapf A, Hamilton JA, Ntziachristos V, et al. Atheroma susceptible to thrombosis exhibit impaired endothelial permeability in vivo as assessed by nanoparticle-based fluorescence molecular imaging. Circ Cardiovasc Imaging 2017;10(5) doi:https://doi.org/10.1161/CIRCIMAGING.116.005813.

36.

Wang Y, Chen J, Yang B, Qiao H, Gao L, Su T, et al. In vivo MR and fluorescence dual-modality imaging of atherosclerosis characteristics in mice using profilin-1 targeted magnetic nanoparticles. Theranostics. 2016;6(2):272–86. https://doi.org/10.7150/thno.13350.CrossRefPubMedPubMedCentral

37.

Grootaert MOJ, Moulis M, Roth L, Martinet W, Vindis C, Bennett MR, et al. Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis. Cardiovasc Res. 2018;114(4):622–34. https://doi.org/10.1093/cvr/cvy007.CrossRefPubMed

38.

Winkels H, Ehinger E, Ghosheh Y, Wolf D, Ley K. Atherosclerosis in the single-cell era. Curr Opin Lipidol. 2018;29(5):389–96. https://doi.org/10.1097/MOL.0000000000000537.CrossRefPubMed

39.

Winkels H, Ehinger E, Vassallo M, Buscher K, Dinh HQ, Kobiyama K, et al. Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry. Circ Res. 2018;122(12):1675–88. https://doi.org/10.1161/CIRCRESAHA.117.312513.CrossRefPubMedPubMedCentral

40.

Cochain C, Vafadarnejad E, Arampatzi P, Pelisek J, Winkels H, Ley K, et al. Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res. 2018;122(12):1661–74. https://doi.org/10.1161/CIRCRESAHA.117.312509.CrossRefPubMed

41.

Cole JE, Park I, Ahern DJ, Kassiteridi C, Danso Abeam D, Goddard ME, et al. Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity. Cardiovasc Res. 2018;114(10):1360–71. https://doi.org/10.1093/cvr/cvy109.CrossRefPubMedPubMedCentral

42.

Konopka CJ, Wozniak M, Hedhli J, Ploska A, Schwartz-Duval A, Siekierzycka A, et al. Multimodal imaging of the receptor for advanced glycation end-products with molecularly targeted nanoparticles. Theranostics. 2018;8(18):5012–24. https://doi.org/10.7150/thno.24791.CrossRefPubMedPubMedCentral

43.

Majmudar MD, Yoo J, Keliher EJ, Truelove JJ, Iwamoto Y, Sena B, et al. Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circ Res. 2013;112(5):755–61. https://doi.org/10.1161/CIRCRESAHA.111.300576.CrossRefPubMedPubMedCentral

44.

Keliher EJ, Ye YX, Wojtkiewicz GR, Aguirre AD, Tricot B, Senders ML, et al. Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease. Nat Commun. 2017;8:14064. https://doi.org/10.1038/ncomms14064.CrossRefPubMedPubMedCentral

45.

Lee JM, Choudhury RP. Atherosclerosis regression and high-density lipoproteins. Expert Rev Cardiovasc Ther. 2010;8(9):1325–34. https://doi.org/10.1586/erc.10.108.CrossRefPubMed

46.

Brown WV, Brewer HB, Rader DJ, Schaefer EJ. HDL as a treatment target. J Clin Lipidol. 2010;4(1):5–16. https://doi.org/10.1016/j.jacl.2009.12.005.CrossRefPubMed

47.

Karalis I, Jukema JW. HDL mimetics infusion and regression of atherosclerosis: is it still considered a valid therapeutic option? Curr Cardiol Rep. 2018;20(8):66. https://doi.org/10.1007/s11886-018-1004-9.CrossRefPubMedPubMedCentral

48.

Mulder WJM, van Leent MMT, Lameijer M, Fisher EA, Fayad ZA, Perez-Medina C. High-density lipoprotein nanobiologics for precision medicine. Acc Chem Res. 2018;51(1):127–37. https://doi.org/10.1021/acs.accounts.7b00339.CrossRefPubMed

49.

Zheng KH, van der Valk FM, Smits LP, Sandberg M, Dasseux JL, Baron R, et al. HDL mimetic CER-001 targets atherosclerotic plaques in patients. Atherosclerosis. 2016;251:381–8. https://doi.org/10.1016/j.atherosclerosis.2016.05.038.CrossRefPubMed

50.

Tang J, Lobatto ME, Hassing L, van der Staay S, van Rijs SM, Calcagno C, et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci Adv. 2015;1(3):e1400223. https://doi.org/10.1126/sciadv.1400223.CrossRefPubMedPubMedCentral

51.

Seijkens TTP, van Tiel CM, Kusters PJH, Atzler D, Soehnlein O, Zarzycka B, et al. Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis. J Am Coll Cardiol. 2018;71(5):527–42. https://doi.org/10.1016/j.jacc.2017.11.055.CrossRefPubMedPubMedCentral

52.

Wen S, Liu DF, Cui Y, Harris SS, Chen YC, Li KC, et al. In vivo MRI detection of carotid atherosclerotic lesions and kidney inflammation in ApoE-deficient mice by using LOX-1 targeted iron nanoparticles. Nanomedicine. 2014;10(3):639–49. https://doi.org/10.1016/j.nano.2013.09.009.CrossRefPubMed

53.

Mitra S, Goyal T, Mehta JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther. 2011;25(5):419–29. https://doi.org/10.1007/s10557-011-6341-5.CrossRefPubMed

54.

Nie S, Zhang J, Martinez-Zaguilan R, Sennoune S, Hossen MN, Lichtenstein AH, et al. Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles. J Control Release. 2015;220(Pt A):61–70. https://doi.org/10.1016/j.jconrel.2015.10.004.CrossRefPubMedPubMedCentral

55.

Tarin C, Carril M, Martin-Ventura JL, Markuerkiaga I, Padro D, Llamas-Granda P, et al. Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI. Sci Rep. 2015;5:17135. https://doi.org/10.1038/srep17135.CrossRefPubMedPubMedCentral

56.

Beldman TJ, Senders ML, Alaarg A, Perez-Medina C, Tang J, Zhao Y, et al. Hyaluronan nanoparticles selectively target plaque-associated macrophages and improve plaque stability in atherosclerosis. ACS Nano. 2017;11(6):5785–99. https://doi.org/10.1021/acsnano.7b01385.CrossRefPubMedPubMedCentral

57.

Luehmann HP, Detering L, Fors BP, Pressly ED, Woodard PK, Randolph GJ, et al. PET/CT imaging of chemokine receptors in inflammatory atherosclerosis using targeted nanoparticles. J Nucl Med. 2016;57(7):1124–9. https://doi.org/10.2967/jnumed.115.166751.CrossRefPubMedPubMedCentral

58.

Bagalkot V, Deiuliis JA, Rajagopalan S, Maiseyeu A. "Eat me" imaging and therapy. Adv Drug Deliv Rev. 2016;99(Pt A:2–11. https://doi.org/10.1016/j.addr.2016.01.009.CrossRefPubMedPubMedCentral

59.

Poh S, Putt KS, Low PS. Folate-targeted dendrimers selectively accumulate at sites of inflammation in mouse models of ulcerative colitis and atherosclerosis. Biomacromolecules. 2017;18(10):3082–8. https://doi.org/10.1021/acs.biomac.7b00728.CrossRefPubMed

60.

Moreno-Layseca P, Icha J, Hamidi H, Ivaska J. Integrin trafficking in cells and tissues. Nat Cell Biol. 2019;21:122–32. https://doi.org/10.1038/s41556-018-0223-z.CrossRefPubMed

61.

Chen CL, Siow TY, Chou CH, Lin CH, Lin MH, Chen YC, et al. Targeted superparamagnetic iron oxide nanoparticles for in vivo magnetic resonance imaging of T-cells in rheumatoid arthritis. Mol Imaging Biol. 2017;19(2):233–44. https://doi.org/10.1007/s11307-016-1001-6.CrossRefPubMed

62.

Capolla S, Garrovo C, Zorzet S, Lorenzon A, Rampazzo E, Spretz R, et al. Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies. Int J Nanomedicine. 2015;10:4099–109. https://doi.org/10.2147/IJN.S78995.CrossRefPubMedPubMedCentral

63.

Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106(23):2894–900.CrossRef

64.

Doring Y, Soehnlein O, Weber C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ Res. 2017;120(4):736–43. https://doi.org/10.1161/CIRCRESAHA.116.309692.CrossRefPubMed

65.

Pertiwi KR, van der Wal AC, Pabittei DR, Mackaaij C, van Leeuwen MB, Li X, et al. Neutrophil extracellular traps participate in all different types of thrombotic and haemorrhagic complications of coronary atherosclerosis. Thromb Haemost. 2018;118(6):1078–87. https://doi.org/10.1055/s-0038-1641749.CrossRefPubMed

66.

Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5. https://doi.org/10.1126/science.1092385.CrossRefPubMed

67.

Pellico J, Lechuga-Vieco AV, Almarza E, Hidalgo A, Mesa-Nunez C, Fernandez-Barahona I, et al. In vivo imaging of lung inflammation with neutrophil-specific (68)Ga nano-radiotracer. Sci Rep. 2017;7(1):13242. https://doi.org/10.1038/s41598-017-12829-y.CrossRefPubMedPubMedCentral

Title: Nanoparticle Imaging of Vascular Inflammation and Remodeling in Atherosclerotic Disease
Author: Darren G. Woodside
Publication date: 01-07-2019
Publisher: Springer US
Keywords: Arterial Occlusive Disease
Positron Emission Tomography
Published in: Current Cardiovascular Imaging Reports / Issue 7/2019
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-019-9501-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties